The number of recalls in 2025 marks second-highest annual total in seven years, as regulatory turbulence reshapes industry risk: Sedgwick.

This year, four individuals were selected as the 2026 Life Sciences & Pharmaceuticals Power Broker winners.

The fast-moving and highly regulated life sciences and pharmaceuticals space demands a high degree of broker specialization.

Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff.

Affected units spike 201% despite fewer overall recall events, signaling evolving risk landscape for manufacturers and insurers, Sedgwick reports.

As aging demographics and technological advances fuel explosive expansion in the pharmaceutical and life sciences industries, companies face mounting challenges in securing talent and facilities and should investigate appropriate risk management solutions.

All five major industries analyzed saw increased recall activity amid regulatory shifts and AI-driven oversight changes: Sedgwick.

High-cost health claims jumped 29% in the past year and 61% over four years, with cancer leading the surge and nearly 90% of self-funded employers hit by catastrophic expenses, Sun Life reports.

Gallagher’s Sarah Palmer shares her career journey and the projects making life science brokering an interesting and fulfilling path.

Tory Agnich, chief underwriting officer for middle market life sciences at Liberty Mutual and 2025 Executive to Watch, discusses the evolving pharmaceutical and life sciences sector.

This year five brokers were selected as Pharmaceuticals Power Brokers. An additional two were named as finalists.

Product recalls surge across key industries in 2024, with over 580 million units affected through September alone, Sedgwick’s quarterly analysis reveals.

This year 6 brokers were selected as Pharmaceuticals Power Brokers. An additional five were named finalists.

The pandemic underscored the dangers of lengthy biotech and pharma supply chains, but there are strategies for better quality control transparency.

In the evolving clinical trials space, independent insurance agents play a key role in helping life sciences firms mitigate new risks.

This year, 6 brokers from across the brokerage field were named as the 2023 Pharmaceuticals Power Broker winners. An additional three brokers were named as finalists.

Digital transformation, clinical trials, climate change and product recalls are among the top risks and opportunities facing the life sciences sector over the next several years.

This year, brokers from across the brokerage field were named as the 2022 Pharmaceuticals Power Broker winners. An additional brokers were named as finalists.

Many thought leaders accurately predicted that the COVID-19 pandemic would not have a negative impact on workers’ compensation claims outcomes. But from a statistical perspective, the pandemic did warp workers’ comp pharmacy data.

Six commercial insurance brokers in the pharmaceutical sector were named 2021 Power Brokers. One additional broker was named a finalist.